Diagnostic Approach, Clinical Implications and Management of Clonal Cytopenia of Undetermined Significance

Due to demographic aging of the general population, cytopenia and especially anemia unknown origin is on rise, with an increasing need for a structured clinical assessment these conditions. The advent next-generation sequencing (NGS) in our practice has facilitated detection clonal hematopoiesis (CH), which present more than 20−40% individuals above 80 years age. This poses unprecedented challenges as CH, undetermined significance (CCUS), associated development myeloid malignancies, cardiovascular diseases other chronic inflammatory-degenerative CH comprises array entities that are distinct from overt but consensus recommendations currently lacking management affected patients. Many questions remain unsolved, such patients unclear should undergo molecular testing, what distinguishes age-associated hematological malignancy, how impacts comorbidities might be most appropriate treatment plan. In this review, we provide approach summarize implications well current CCUS